Genetic testing in primary care

Annual Review of Genomics and Human Genetics

Volumn 5, Issue , 2004, Pages 1-14

  Burke, Wylie ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Family history; Gene variant; Mutation; Prevention; Risk

Indexed keywords

DECISION MAKING; FAMILY HISTORY; GENETIC ANALYSIS; GENETIC RISK; HUMAN; MASS SCREENING; POLICY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; REVIEW; RISK ASSESSMENT; SYMPTOMATOLOGY;

CLINICAL COMPETENCE; DECISION MAKING; GENETIC SCREENING; HUMANS; PHARMACOGENETICS; PRIMARY HEALTH CARE; REPRODUCTION; RISK ASSESSMENT;

EID: 5444262324     PISSN: 15278204     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.genom.5.061903.180029     Document Type: Review

References (78)

1. Am. Coll. Obstet. Gynecol. Comm. Pr. Bull. ACOG Pr. Bull. 2001. Clinical management guidelines for obstetricians-gynecologists. Prenatal diagnosis of fetal chromosome abnormalities. Obstet. Gynecol. 97(Suppl.):1-12
2. Am. Soc. Clin. Oncol. 2003. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J. Clin. Oncol. 21:2397-406
3. Am. Soc. Human Genetics. 1975. Genetic counseling. Am. J. Hum. Genet. 27:240-42
4. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, et al. 2003. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72:1117-30
5. Armstrong K, Weber B, Ubel PA, Guerra C, Schwartz JS. 2002. Interest in BRCA1/2 testing in a primary care population. Prev. Med. 34:590-95
6. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, et al. 2000. Pharmacogenetic prediction of clozapine response. Lancet 355:1615-16
7. Begg C. 2002. On the use of familial aggregation in population-based case probands for calculating penetrance. J. Natl. Cancer Inst. 94:1221-26
8. Braithwaite D, Sutton S, Smithson WH, Emery J. 2002. Internet-based risk assessment and decision support for the management of familial cancer in primary care: a survey of GPs' attitudes and intentions. Fam. Pract. 19:587-90
9. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, et al. 2001. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86:5658-71
10. Burke W, Thomson E, Khoury MJ, McDonnell SM, Press N, et al. 1998. Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA 280:172-78
11. Burke W, Pinsky L, Press N. 2001. Categorizing genetic tests to identify their ethical, legal and social implications. Am. J. Med. Genet. (Semin. Med Genet.) 106:233-40
12. Burke W, Reyes M, Imperatore G. 2002. Hereditary haemochromatosis: a realistic approach to prevention of iron overload disease in the population. Best. Pract. Res. Clin. Haematol. 15:315-28
13. Campbell TL, McDaniel SH, Cole-Kelly K, Hepworth J, Lorenz A. 2002. Family interviewing: a review of the literature in primary care. Fam. Med. 34:312-18
14. Cao A, Rosatelli MC, Monni G, Glanello R. 2002. Screening for thalassemia: a model of success. Obstet. Gynecol. Clin. North Am. 29:305-28
15. Clayton EW. 1998. What should the law say about disclosure of genetic information to relatives? J. Health Care Law Policy 1:373-90
16. Collins FS. 1997. Preparing health professionals for the genetic revolution. JAMA 278:1285-86
17. Collins FS. 1999. Shattuck lecture: medical and societal consequences of the Human Genome Project. N. Engl. J. Med. 341:28-37
18. Creinen MD, Lisman R, Strickler RC. 1999. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil. Steril. 72:646-51
19. deBock GH, Vliet Vlieland TP, Hageman GC, Oosterwijk JC, Springer MP, Kievit J. 1999. The assessment of genetic risk of breast cancer: a set of GP guidelines. Fam. Pract. 16:71-77
20. DeDecker HP, Lawrenson JB. 2001. The 22q11.2 deletion: from diversity to a single gene theory. Genet. Med. 3:2-5
21. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Rossi E, et al. 2001. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br. J. Haematol. 113:630-35
22. Dubois S, Kowdley K. 2003. The importance of screening for hemochromatosis. Arch. Intern. Med. 163:2424-25
23. Emmerich J, Rosendaal F, Cattaneo M, Margaglione M, De Stefano V, Cumming T. 2001. Combined effect of factor V Leiden and prothroimbin 20210A on the risk of venous thromboembolism - pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study group for pooled-analysis in venous thromboembolism. Thromb. Haemostat. 86:809-16
24. Evans JP, Skrzynia C, Burke W. 2001. The complexities of predictive genetic testing. Br. Med. J. 322:1052-56
25. Friedman JM. 2002. Neurofibromatosis 1. GeneTests Web Site, http://www.geneclinics.org
26. Giardiello FM, Brensinger JD, Petersen GM, Luce MC, Hylind LM, et al. 1997. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N. Engl. J. Med. 336:823-27
27. Glover DW, Maron BJ. 1998. Profile of preparticipation cardiovascular screening for high school athletes. JAMA 279:1817-19
28. Gollust SE, Hull SC, Wilfond BS. 2002. Limitations of direct-to-consumer advertising for clinical genetic testing. JAMA 288(14):1762-67
29. Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ. 2001. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet. Med. 3:149-54
30. Harris R, Lane B, Harris H, Williamson P, Dodge J, et al. 1999. National confidential enquiry into counselling for genetic disorders by non-geneticists: general recommendations and specific standards for improving care. Br. J. Obstet. Gynaecol. 106:658-63
31. Hirsh J, Lee AY. 2002. How we diagnose and treat deep venous thrombosis. Blood 99:3102-10
32. Holtzman NA, Watson MS. 1999. Promoting safe and effective genetic testing in the United States. Final report of the task force on genetic testing. Baltimore: Johns Hopkins Press
33. Hubbard R, Lewontin RC. 1996. Pitfalls of genetic testing. N. Engl. J. Med. 334:1192-94
34. Kaback MM. 2000. Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model. Eur. J. Pediatr. 159(Suppl. 2):S192-95
35. Kaprio J. 2000. Genetic epidemiology. Br. Med. J. 320:1257-59
36. Khoury MJ, Thrasher JF, Burke W, Gettig EA, Fridinger F, Jackson R. 2000. Challenges in communicating genetics: a public health approach. Genet. Med. 2:198-202
37. Lane B, Williamson P, Dodge JA, Harris H, Super M, Harris R. 1997. Confidential inquiry into families with two siblings with cystic fibrosis. Arch. Dis. Child. 77:501-3
38. Lapham EV, Kozma C, Weiss JO. 1996. Genetic discrimination: perspectives of consumers. Science 274:621-24
39. Low L, King S, Wilkie T. 1998. Genetic discrimination in life insurance: empirical evidence from a cross-sectional survey of genetic support groups in the Untied Kingdom. Br. Med. J. 317:1632-35
40. Marteau TM, Lerman C. 2001. Genetic risk and behavioural change. Br. Med. J. 322:1056-59
41. Martinelli I, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Mannucci PM. 2000. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br. J. Haematol. 111:1223-29
42. Masellis M, Basile V, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL. 2000. Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biol. Psychiatry. 47:252-66
43. McDonald-McGinn DM, Tonnesen MK, Laufer-Cahana A, Finucane B, Driscoll DA, et al. 2001. Phenotype of the 22q11.2 deletion in individuals identified through an affected relative: cast a wide FISHing net! Genet. Med. 3:23-29
44. McDonnell SM, Parrish RG. 2003. Hereditary hemochromatosis and its elusive natural history. Arch. Intern. Med. 163:2421-23
45. McLeod HL, Krynetski EY, Relling MV, Evans WE. 2000. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14:567-72
46. Mickle JE, Cutting GR. 1998. Clinical implications of cystic fibrosis transmembrane conductance regulator mutations. Clin. Chest Med. 19:443-58
47. Middeldorp S, Meinardi JR, Koopman MM, van Pampus EC, Hamulyak K, et al. 2001. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann. Intern. Med. 135:322-27
48. Mouchawar J, Valentine Goins K, Somkin C, Puleo E, Hensley Alford S, et al. 2003. Guidelines for breast and ovarian cancer genetic counseling referral: adoption and implementation in HMOs. Genet. Med. 5:444-50
49. Natl. Cholest. Educ. Progr. (NCEP) Expert Panel Detect., Eval. Treat. High Cholest. Adults (Adult Treat. Panel II). 1993. Summary of the second report of the expert panel. JAMA 269:3015-23
50. Pate v. Threlkel. 1995. 661 So.2d 278 Florida
51. Pagon RA, Pinsky L, Beahler C. 2001. Online medical genetics resources: a U.S. perspective. Br. Med. J. 322:1035-38
52. Pergament E. 2000. New molecular techniques for chromosome analysis. Baillieres Best Pract. Res. Clin. Obstet. Gynaecol. 14:677-90
53. Powell LW, George K, McDonnell SM, Kowdley KV. 1998. Diagnosis of hemochromatosis. Ann. Intern. Med. 129:925-31
54. Reich LM, Bower M, Key NS. 2003. Role of the geneticist in testing and counseling for inherited thrombophilia. Genet. Med. 5:133-43
55. Rich EC, Burke W, Heaton CJ, Haga S, Pinsky L, et al. 2004. Revitalizing the family history in primary care. J. Gen. Intern. Med. 19:273-80
56. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, et al. 2003. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N. Engl. J. Med. 348:1425-34
57. Rosendal F. 1993. Venous thrombosis: a multicausal disease. Lancet 353:1167-73
58. Rose PW, Watson E, Yudkin P, Emery J, Murphy M, et al. 2001. Referral of patients with a family history of breast/ovarian cancer-GPs' knowledge and expectations. Fam. Pract. 18:487-90
59. Safer v. Pack. 1996. 677 A. 2d 1188 NJ
60. Schroy PC 3rd, Barrison AF, Ling BS, Wilson S, Geller AC. 2002. Family history and colorectal cancer screening: a survey of physician knowledge and practice patterns. Am. J. Gastroenterol. 97:1031-36
61. Severin MJ. 1999. Genetic susceptibility for specific cancers: medical liability of the clinician. Cancer 86:2564-69
62. Simioni P, Sanson BJ, Prandoni P, Tormene D, Friederich PW, et al. 1999. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb. Haemost. 81:198-202
63. Starfield B. 1994. Is primary care essential? Lancet. 344:1129-33
64. Stewart A, Haites N, Rose P. 2001. Online medical genetics resources: a U.K. perspective. Br. Med. J. 322:1037-39
65. Suchard MA, Yudkin P, Sinheimer JS. 1999. Are general practitioners willing and able to provide genetic services for common diseases. J. Genet. Couns. 8:301-11
66. Suther S, Goodson P. 2003. Barriers to the provision of genetic services by primary care physicians: a systematic review of the literature. Genet. Med. 5:70-76
67. Sweet KM, Bradley TL, Westman JA. 2002. Identification and referral of families at high risk for cancer susceptibility. J. Clin. Oncol. 20:528-37
68. Task Force Newborn Screening. 2000. Newborn screening: a blueprint for the future - a call for a national agenda on state newborn screening programs. Pediatrics 106:389-422
69. st Century: Incorporating Genetics into Primary Health Care. Plainview NY: Cold Spring Harbor Lab. Press
70. Watson E, Clements A, Yudkin P, Rose P, Bukach C, et al. 2001. Evaluation of the impact of two educational interventions on GP management of familial breast/ovarian cancer cases: a cluster randomized controlled trial. Br. J. Gen. Pract. 51:817-21
71. Welch HG, Burke W 1998. Uncertainties in genetic testing for chronic disease. JAMA 280:1525-27
72. Weinshilboum R. 2003. Inheritance and drug response. N. Engl. J. Med. 348:529-37
73. Weisner G, Snow K. 2003. Multiple endocrine neoplasia type 2. Gene Rev. http://www.genetests.org
74. Wells D, Delhanty JD. 2001. Preimplantation genetic diagnosis: applications for molecular medicine. Trends Mol. Med. 7:23-30
75. Wilkins-Haug L, Erickson K, Hill L, Power M, Holzman GB, Schulkin J. 2000. Obstetrician-gynecologists' opinions and attitudes on the role of genetics in women's health. J. Womens Health Gend. Based Med. 9:873-79
76. Williams RR, Hopkins PN, Wu LL, Hunt SC. 2000. Applying genetic strategies to prevent atherosclerosis. In Genetics and Public Health, ed. MJ Khoury, W Burke, E Thomson, pp. 463-85. New York: Oxford Univ. Press
77. Winawer S, Reicher R, Rex D, Bond J, Burt R, et al. 2003. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 124:544-60
78. Yoon PW, Scheuner MT, Peterson-Oehlke KL, Gwinn M, Faucett A, Khoury MJ. 2002. Can family history be used as a tool for public health and preventive medicine? Genet. Med. 4:304-10